Overview

A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Pharmacokinetics, pharmacodynamics and tolerability of AOP200704 infusion is compared to that of Esmolol by measurement of plasma concentrations of AOP200704, esmolol and their metabolites, by assessing the effect of both drugs on dobutamine-induced tachycardia, and by monitoring vital signs, ECG and adverse events.
Phase:
Phase 2
Details
Lead Sponsor:
AOP Orphan Pharmaceuticals AG
Treatments:
Esmolol